Dublin, Dec. 15, 2016 -- Research and Markets has announced the addition of the "R&D Drug Pipeline Database" newsletter to their offering.
R&D Drug Pipeline Database: 1-Year Subscription
Subscription to La Merie Publishing's proprietary R&D Drug Pipeline Database provides 24/7 online access to information about more than 21,000 project entries (files) for therapeutic drugs on the market and on investigational drug candidates in research & development.
Pre-established and free search functions allow to identify molecules according to their:
- Product category (NCE, antibodies, proteins, DNA, RNA, cells, vaccines, peptides)
- Technology (e.g. antibody-drug conjugate, bispecific antibody)
- Target (e.g. Her2, Amyloid beta, TNF, PD-1/PD-L1)
- Pipelines (selected by target, therapeutic area, company, technology)
- Sales (for marketed antibodies, peptides and proteins)
- R&D Phase (clinical phases, market, preclinical)
- Territory (countrywise)
- Therapeutic Area (e.g. infectious, oncology, gastrointestinal)
- Drug Code/Name (for individual molecules)
Each project is specified for its Target, Therapeutic Area and R&D Phase. Use of the R&D Drug Pipeline Database is intuitive. Data sets of interest can be printed and exported as reports in Excel or Word format. Projects are being updated continuously. The R&D history of each project with online references of information sources can be viewed and printed. Sales figures of major therapeutic antibodies, proteins and peptides on the market are provided.
An advanced search function allows to combine search parameters. A scroll down menu for predefined targets and technologies conveniently selects projects of interest. By clicking on column heads of the project list, projects can be arranged in ascending or descending alphabetical or numerical order, e.g. for phase or company name.
Special Focus of the Database:
- Antibodies
- Proteins
- Peptides
- Vaccines
Purchase of the subscription provides a 1-year online access to the data of the R&D Drug Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase.
Benefits from the R&D Drug Pipeline Database:
- Intuitive use
- 24/7 online access
- Designed for structured searches
- Focused on targets, product categories and R&D phases
- Ideal for competitor analysis (companies, targets, product categories)
- Cost-effective and rapid solution for benchmarking
- Identification of licensing candidates
Project listing in a tabular format:
- Drug Codes
- Target/Mechanism of Action
- Class of Compound
- Product Category
- Company
- Territory
- Therapeutic Area
- Indication
- R&D Phase
Product Categories:
- Antibody
- Cell
- DNA
- Peptide
- Protein
- RNA
- Small Molecule
- Vaccine
Therapeutic Areas:
- Cardiovascular, blood & acute care
- Dermatology
- Gastrointestinal
- Genitourinary, gynecology & renal
- Infectious & toxicology
- Metabolism & endocrine
- Neurology & psychiatry
- Oncology
- Ophthalmolgoy & otorhinolaryngology
- Orthopedics, dental, anesthesia & surgery
- Pulmonary & respiratory
- Rheumatoid & autoimmune
Examples of Predefined Targets of the Scroll Down Menu:
- Antibody-Drug Conjugates (ADC)
- Sales of Antibodies & Proteins 2015
- CAR & TCR Engineered T-Cells and NK Cells
- Adalimumab (Humira) Biosimilars
- Her2 Antibodies
- Amyloid beta-Targeted Antibodies
- CD10-Targeted Immunotherapeutics
- Immunocytokines
- Bispecific Antibodies
- Peptide Sales 2015
- PD-1 & PD-L1 Immune Checkpoint Inhibitors
- Zika Virus Vaccines
- Coagulation Factors
- Botulinum Neurotoxins
- Human Papilloma Virus (HPV) Vaccines & Therapeutics
- G-CSF & GM-CSF
- PTH-R Agonists
- Cardiometabolic Peptides
- Immune Checkpoint Modulators
Examples of Predefined Technologies of the Scroll Down Menu:
- Transgenic XenoMouse Antibodies
- T-Cell Redirecting Bispecific Antibodies
- ADC - Pyrrolobenzodiazepine (PBD)
- Fc-Fusion Proteins
- Oligo- and Polyclonal Antibodies
For more information about this newsletter visit http://www.researchandmarkets.com/research/xzv96n/randd_drug
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Drug Discovery


Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 



